Used in the treatment of multiple myeloma, this antibody targets SLAMF7 (CS1), a protein highly expressed on malignant plasma cells. It enables immune-mediated destruction of cancer cells through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The antibody enhances natural killer (NK) cell activity, promoting targeted elimination of tumor cells while sparing normal tissues. It is utilized both as a standalone therapy and in combination with other agents such as immunomodulatory drugs or proteasome inhibitors to improve clinical outcomes in relapsed or refractory disease.